Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official VSports app下载. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2006 Oct;12(10):1056-64.
doi: 10.1016/j.bbmt.2006.06.004.

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia

Jennifer R Brown  1 , Haesook T Kim, Shuli Li, Katherine Stephans, David C Fisher, Corey Cutler, Vincent Ho, Stephanie J Lee, Edgar L Milford, Jerome Ritz, Joseph H Antin, Robert J Soiffer, John G Gribben, Edwin P Alyea
Affiliations
Free article

"V体育官网入口" Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia

Jennifer R Brown et al. Biol Blood Marrow Transplant. 2006 Oct.
Free article

Abstract

Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear. In this analysis, we report the outcomes of 46 patients with advanced CLL who underwent nonmyeloablative stem cell transplantation (NST) from HLA-matched unrelated (67%) or related (33%) donors. Fludarabine (30 mg/m2 x 4) and low-dose intravenous busulfan (0. 8 mg/kg/day x 4) were used for conditioning. The 2-year overall survival (OS) and progression-free survival (PFS) rates in this refractory patient population were 54% and 34%, respectively, with a median follow-up of 20 months. The primary cause of treatment failure was relapse, with a 2-year cumulative incidence of 48%. High hematopoietic donor chimerism > or = 75% at day +30 was a significant predictor of 2-year PFS (47% vs 11%; P = . 03). In multivariate analysis, chemotherapy-refractory disease at transplantation was associated with a 3. 2-fold risk of progression (P = . 01) and a 4. 6-fold risk of death (P = . 02) VSports手机版. Increasing number of previous therapies and increasing bone marrow involvement were also associated with decreased PFS and OS. These results suggest that NST using fludarabine and low-dose intravenous busulfan is a reasonable treatment option for patients with advanced CLL, but that NST earlier in the disease course will likely be needed to achieve long-term disease control in a high proportion of patients. .

PubMed Disclaimer

Publication types

MeSH terms

Substances (V体育安卓版)

LinkOut - more resources